AzTrials
AzTrials

Rheumatoid ArthritisNCT02652299

Fibrocytes in Early and Longstanding Rheumatoid Arthritis

An observational study of Rheumatoid Arthritis, run by Odense University Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will focus on a rare cell population called fibrocytes in peripheral blood and synovial tissue in Rheumatoid Arthritis (RA). One group of patients with early RA and one group with long-standing RA. Both groups will be followed for 6 months. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Synovial biopsy
How many people
60 participants
Where
1 siteDenmark
Study dates
Mar 2016to 4 Apr 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Following informed written consent, RA patients will be enrolled from Odense University Hospital (OUH) during a 12 month period.

Who may be able to join

  • Patients with newly diagnosed RA (according to 2010 classification criteria) who have been diagnosed ≤ 6 months, and who have at least one swollen joint in hands/fingers.
  • Patients with longstanding RA (>5 years duration).
  • Ability and willingness to give written informed consent and to meet the requirements of this protocol.

Who cannot join

  • Age < 18 years.
  • Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis or primary vasculitis.
  • History of or current inflammatory joint disease other than RA (e.g. gout, reactive arthritis, psoriatic arthritis, spondyloarthropathy, Lyme disease).
  • Allergy to local aesthetics.
  • Hereditary or acquired (e.g. Anticoagulant Treatment, apart from low dose aspirin) coagulation abnormality.
  • Prednisolone above 7.5 mg/day
Show all 12Show fewer
  • Skin pathology at site of joint biopsy.
  • Obesity, BMI > 30.
  • Functional class IV as defined by the criteria for classification of functional status in RA.
  • Heart failure (NYHA class III/IV), immunodeficiency, current or past malignant disease (except for non-melanoma skin cancer), recurrent or chronic infections (viral, fungal or bacterial), inflammatory bowel disease, myeloproliferative disorder or other bone marrow disease.
  • Severe nervous system, liver, pulmonary, renal or endocrine disease (including Type 1 diabetes, stable type 2 diabetes is allowable).
  • Major surgery within 8 weeks. Laboratory exclusion Criteria Platelet count <100 x 109 /L or Haemoglobin <5 mmol/L or White blood cells <3 x 109/L or estimated Glomerular Filtration Rate (eGFR) <60.

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Odense University Hospital

    Odense, 5000

Other trials in Denmark

About this study

This study will focus on a rare cell population called fibrocytes in peripheral blood and synovial tissue in Rheumatoid Arthritis (RA). One group of patients with early RA and one group with long-standing RA. Both groups will be followed for 6 months.

After informed and written consent a control groups is also formed: One for synovial biopsies for patients undergoing a routine arthroscopy, where a peripheral blood sample is also taken.

The hypothesis is that fibrocytes are present in the blood and synovial tissue in RA. Patients with early and long-standing RA have higher concentrations of fibrocytes in peripheral blood and synovial tissue compared to a control groups. Levels of fibrocytes in peripheral blood and synovial tissue are correlated with RA disease activity measures and imaging findings.

Read the detailed description

The intimal lining of a synovial joint consists of unique cells called fibroblast-like synoviocytes (FLS cells) with interspersed macrophage-like synoviocytes. In the healthy joint macrophage-like synoviocytes are implicated in the innate immune defence and support adaptive immunity, while FLS cells function to regulate the release of nutrients and molecules, including hyaluronan, into the joint cavity.

Rheumatoid arthritis (RA) is a chronic systemic disease with autoimmune traits, which primarily affects synovial joints. The intimal lining of the synovium expands and exhibits characteristics of unregulated growth and loss of contact inhibition. The expanding synovium degrades cartilage and erodes into the bone at the cartilage-bone interface, creating the hallmark of RA, the joint erosion.

The RA FLS cell, has a markedly different phenotype than the healthy cell, and plays a key role in the destructive process by the release of pro-inflammatory cytokines and matrix destructive enzymes. FLS cells expand during the joint destructive process, however, there is minimal mitotic activity. The origin of the expanding FLS population is therefore uncertain.

Possible explanations to this phenomenon could be decreased senescence, migration of mesenchymal stem cells from the circulation, epithelial to mesenchymal cell-transition or expansion of a stem cell pool in the synovium. FLS precursors could also migrate to the synovium through pores in cortical bone, as has been demonstrated in mice with collagen-induced arthritis. In a murine model, it has further been shown that RA FLS cells can spread via the systemic circulation from one joint and attack previously unaffected joints.

A possible FLS cell precursor has been identified in peripheral blood and called fibrocytes. Fibrocytes are spindle-shaped cells that express surface receptors of both stromal and hematopoietic cells. The fibrocytes are a rare (~0.5% of leukocytes) population of bone marrow derived mesenchymal progenitor cells. A combination of markers that distinguish fibrocytes from monocytes, macrophages and fibroblasts has been described. In vitro circulating human peripheral blood mononuclear cells and monocytes (CD14+) can differentiate into fibrocytes. Fibrocytes can differentiate in vitro along multiple mesenchymal lineages into adipocytes, chondrocytes, myofibroblasts and osteoblasts. It is unknown which differentiation pathway occurs in vivo or if multiple differentiation profiles can occur .

Increased numbers of circulating fibrocytes have been found in murine RA models. In a small sample of RA patients (six patients, ten controls), peripheral blood fibrocytes had elevated phosphorylation activation compared to controls, and cells were demonstrated in the synovium. Here fibrocyte activation was correlated with arthritis disease activity (DAS28). In a murine model, activated circulating fibrocytes where found to migrate to arthritis joints in the preclinical phase of the disease, and to accumulate in the FLS cell layer of the synovium. Adoptive transfer of circulating fibrocytes in this murine model, led to worsening of joint disease indicating that circulating fibrocytes are involved in RA joint pathology, possibly as a FLS-cell precursor. Further, fibrocytes have also been implicated in extra articular manifestations of RA, e.g. pericarditis (murine model), atherosclerosis, and interstitial lung disease.

Studies on synovial biopsies have been critical in the understanding of RA pathogenesis. A new method of collecting synovial tissue, ultrasound-guided synovial biopsy is safe and well tolerated by patients and reliable for collecting high quality synovial tissue from large and small joints.

Being tested
Synovial biopsy
Keywords
Fibrocytes, Synovial biopsy
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Synovial biopsyBiological

    Synovial tissue for analysis and biobank.

Study groups in NCT02652299
Study groupRoleWhat they receive
Early Rheumatoid Arthritis groupFollowing informed written consent, 20 patients with early RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
Receives: Biological: Synovial biopsy
Longstanding Rheumatoid Arthritis groupFollowing informed written consent, 20 patients with longstanding RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
Receives: Biological: Synovial biopsy
Control group: Synovial tissue and peripheral blood20 Non-RA patients who are referred to arthroscopy in a joint of the hand at OUH Department of Orthopedics, Section of hand surgery, are asked to participate by the surgeon at the first ambulatory consultation. Following informed written consent, MRI of hand, a blood sample and synovial biopsies, will be used as control for synovial and plasma fibrocyte levels. The synovial biopsies will be obtained during the planned arthroscopy.
Receives: Biological: Synovial biopsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fibrocytes in the peripheral blood.

    Compare level of fibrocytes (Fibrocytes/uL) in peripheral blood between the group of healthy controls and patients with early and long-standing RA.

    Compare level of fibrocytes (Fibrocytes/uL) at start of observation to end of observation in both RA groups.

    Measured: 6 months

Secondary outcomes (2)
  1. Interstitial lung disease and fibrocyte level.

    Is the fibrocyte level in peripheral blood at presentation correlated with signs of beginning interstitial lung disease, defined as a reduction in the Carbon monoxide diffusion capacity (as mL/min/mm Hg and as a percentage of a predicted value) measured by a lung function test at presentation and at the end of the 6 months period.

    Measured: 6 months

  2. Fibrocytes and RA disease activity by imaging, and synovial tissue analysis.

    Fibrocyte levels are correlated to disease activity measured by imaging findings on x-ray (Larsen Score), ultrasound (Synovitis and Doppler Score (0-3)) and MRI (RAMRIS score) and degree of synovial that inflammation.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2016 (estimated)
  2. Study startMar 2016
  3. Primary completion4 Apr 2018
  4. Study completion4 Apr 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02652299
Sponsor's protocol ID
S-20140062
Status last verified
Mar 2019
First submitted
15 Nov 2015
Last updated
13 Mar 2019
Results posted
No
Data monitoring committee
No

Publications

  • Just SA, Nielsen C, Werlinrud JC, Larsen PV, Hejbol EK, Tenstad HB, Daa Schroder H, Barington T, Torfing T, Humby F, Lindegaard H. Fibrocytes in early and long-standing rheumatoid arthritis: a 6-month trial with repeated synovial biopsy, imaging and lung function test. RMD Open. 2021 Mar;7(1):e001494. doi: 10.1136/rmdopen-2020-001494.

    PubMed 33674419

Questions about this trial

What is this clinical trial studying?

An observational study of Rheumatoid Arthritis, run by Odense University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fibrocytes in the peripheral blood. (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02652299, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2019; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in